Innovation and greater probability of success in drug discovery and development - from target to biomarkers

被引：11

作者：

Kola, I

Hazuda, D

机构：

[1] Basic Res Merck Res Labs, Rahway, NJ 07075 USA

[2] Merck & Co Inc, West Point, PA 19486 USA

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2005年 / 16卷 / 06期

关键词：

D O I：

10.1016/j.copbio.2005.10.014

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：644 / 646

页数：3

共 7 条

[1] Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[2] Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery [J].

Labhasetwar, V .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :674-680

[3] Improving success rates for lead generation using affinity binding technologies [J].

Makara, GM ;

Athanasopoulos, J .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :666-673

[4] Bioluminescence technology for imaging cell proliferation [J].

Momota, H ;

Holland, EC .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :681-686

[5] Skin biopsies for the measurement of clinical pharmacodynamic biomarkers [J].

Phillips, RL ;

Sachs, AB .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :687-690

[6] Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits [J].

Schadt, EE .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :647-654

[7] Functional assays for screening GPCR targets [J].

Thomsen, W ;

Frazer, J ;

Unett, D .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :655-665

← 1 →